Jan H.M. Schellens - Concepedia

Author

Jan H.M. Schellens

Also Known As

H Rosing, J Beijnen, J H M Schellens, J H Schellens, J Schellens, J. H. M. Schellens, J. H. Schellens, J. H.M. Schellens, J. Schellens, J.H. Schellens

1.2K

Publications

58.8K

Citations

111

H-Index

268

Concepts

All Affiliations

The Netherlands Cancer Institute Utrecht University Slotervaartziekenhuis Oncode Institute University Medical Center Utrecht

About

Jan H.M. Schellens is an author at The Netherlands Cancer Institute specializing in medicine, pharmacology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	64	329	19.2K
2	Health Sciences	20	29	1.9K
3	Natural Sciences	19	27	1.6K
4	Engineering	11	13	776
5	Business	2	2	39

Jan H.M. Schellens

616

Publications

44.1K

Citations

H-Index

Page 1

	Year	Citations
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers Peter C.C. Fong, David S. Boss, Timothy A. Yap, New England Journal of Medicine	2009	3.6K
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer Scott Kopetz, Axel Grothey, Rona Yaeger, New England Journal of Medicine	2019	1.4K
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Marc Maliepaard, George L. Scheffer, Ian F. Faneyte, PubMed Breast OncologyImmunologySubcellular LocalizationImmunotherapyCellular Physiology	2001	1.1K
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in <i>BRCA</i> Carrier Ovarian Cancer Correlating With Platinum-Free Interval Peter C.C. Fong, Timothy A. Yap, David S. Boss, Journal of Clinical Oncology	2010	984
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Journal of Clinical Oncology Trametinib TreatmentConclusion DabrafenibMedicineRadionuclide TherapyLocally Advanced	2017	848
A Phase I and Pharmacological Study with Imidazolium-<b> <i>trans-</i> </b>DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent Jeany M. Rademaker-Lakhai, H.J.G.D. van den Bongard, Dick Pluim, Clinical Cancer Research	2004	820
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. John Allen, Arnold van Loevezijn, Jeany M Lakhai, PubMed Bcrp ActivityPharmacotherapyOther Ftc AnaloguesDrug ResistanceMolecular Pharmacology	2002	687
Combined BRAF, EGFR, and MEK Inhibition in Patients with <i>BRAF</i> V600E-Mutant Colorectal Cancer Ryan B. Corcoran, Thierry André, Chloé E. Atreya, Cancer Discovery	2018	563
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial Vivek Subbiah, Ulrik Lassen, Élena Elez, The Lancet Oncology Surgical OncologyOncologyGastrointestinal OncologyBiliary CancerPathology	2020	489
Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918 C.M.F. Kruijtzer, Jos H. Beijnen, Hilde Rosing, Journal of Clinical Oncology	2002	456

Page 1